<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727309</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-HBH001</org_study_id>
    <nct_id>NCT02727309</nct_id>
  </id_info>
  <brief_title>A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients</brief_title>
  <official_title>A Pilot Study of Second-line Treatment With Apatinib After Trans Arterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of TACE combined with apatinib in&#xD;
      treating advanced hepatocellular carcinoma. The primary endpoint is progression-free survival&#xD;
      (PFS), 3-month PFS, 6-month PFS and 1-year PFS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>6 months</time_frame>
    <description>A duration from the date of initial treatment with apatinib to disease progression(as defined by RECIST) or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival (OS) was calculated from the date of initial treatment with apatinib to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rates</measure>
    <time_frame>1.5 months</time_frame>
    <description>Number of participants who achieve complete response or partial response. Either complete response (CR) or partial response (PR) will be evaluated by RECIST, confirmed at least 6 weeks following the date of the initial response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with advanced hepatocellular carcinoma after been treated with TACE receive apatinib (750mg) daily, until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.</description>
    <arm_group_label>apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a histologic or cytologic diagnosis of hepatocellular carcinoma&#xD;
&#xD;
          -  Have progressed after systematic chemotherapy/target therapy, or cannot tolerated with&#xD;
             first-line treatment&#xD;
&#xD;
          -  The previous chemotherapy and the present trial registration must be at least 2 weeks&#xD;
             apart. And they must have recovered from any toxicity of a previous chemotherapy&#xD;
&#xD;
          -  Patients with Child Pugh Class A &amp; B disease are eligible for the study&#xD;
&#xD;
          -  Patients with Barcelona Clinic Liver Cancer stage B or C are eligible for the study&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance score (PS): 0-2&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Hepatitis B virus DNA&lt;2000 IU/ml&#xD;
&#xD;
          -  Adequate organ function meeting the following:&#xD;
&#xD;
               -  Bone marrow: absolute neutrophil count ≥1.5×109/L (1500/mm3); platelet ≥&#xD;
                  75×109/L; hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  Liver: Serum bilirubin ≤ 1.5 ×ULN, AST and ALT ≤ 5 ×ULN, ALB ≥ 29 g/L&#xD;
&#xD;
               -  Kidney: Cr ≤1.5 ×upper limit of normal&#xD;
&#xD;
          -  Within 7 days prior to the start of therapy, women of child-bearing potential must&#xD;
             undergo a pregnancy test, which must be negative; men of child-bearing potential:&#xD;
             contraceptive measures must be adopted during treatment and within 8 weeks afterward&#xD;
&#xD;
          -  Subjects who understand and voluntarily signed a written informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous locoregional therapy within 4 weeks prior to enrollment&#xD;
&#xD;
          -  Diagnosed with cholangiocellular carcinoma, mixed cell carcinoma and fibrolamellar&#xD;
             hepatocellular carcinoma&#xD;
&#xD;
          -  History of other malignancy within 5 years except for non-melanoma skin cancer, cervix&#xD;
             in situ carcinoma&#xD;
&#xD;
          -  Prepared for liver transplantation&#xD;
&#xD;
          -  Patients with contraindications (active bleeding, ulcers, intestinal perforation,&#xD;
             intestinal obstruction, within 30 days after major surgery, uncontrolled high blood&#xD;
             pressure medication, III-IV level cardiac insufficiency, severe liver and kidney&#xD;
             dysfunction)&#xD;
&#xD;
          -  A previous history of Interstitial pulmonary disease, drug-induced interstitial&#xD;
             disease, radiation pneumonitis requiring hormonal therapy or active interstitial lung&#xD;
             disease with any clinical evidence&#xD;
&#xD;
          -  Use of CYP3A4 inhibitor within 7 days or CYP3A4 inducer within 12 days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Patients with central nervous system metastases or brain metastasis&#xD;
&#xD;
          -  Previous definite diagnosis of neuropsychiatric disturbances, including epilepsy or&#xD;
             dementia&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients with bone metastasis received palliative radiation within 4 weeks prior to&#xD;
             enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xu Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu Zhu, MD</last_name>
    <phone>+86-10-88196476</phone>
    <email>drzhuxu@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Interventional Therapy</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Zhu, MD</last_name>
      <phone>+86-10-88196476</phone>
      <email>drzhuxu@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 28, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Zhuxu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Apatinib</keyword>
  <keyword>Second-line Treatment</keyword>
  <keyword>Hepatocellular Cancer</keyword>
  <keyword>TACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

